作者
Yang Gao,Naoe Taira Nihira,Xia Bu,Chen Chu,Jinfang Zhang,Aleksandra S. Kołodziejczyk,Yanli Fan,Ngai Ting Chan,Leina Ma,Jing Liu,Dong Wang,Xiaoming Dai,Huadong Liu,Masaya Ono,Akira Nakanishi,Hiroyuki Inuzuka,Brian J. North,Yhu‐Chering Huang,Samanta Sharma,Yan Geng,Wei Xu,X. Shirley Liu,Lei Li,Yoshio Miki,Piotr Siciński,Gordon J. Freeman,Wenyi Wei
摘要
Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive clinical outcomes for multiple tumours. However, only a subset of patients achieves durable responses, suggesting that the mechanisms of the immune checkpoint pathways are not completely understood. Here, we report that PD-L1 translocates from the plasma membrane into the nucleus through interactions with components of the endocytosis and nucleocytoplasmic transport pathways, regulated by p300-mediated acetylation and HDAC2-dependent deacetylation of PD-L1. Moreover, PD-L1 deficiency leads to compromised expression of multiple immune-response-related genes. Genetically or pharmacologically modulating PD-L1 acetylation blocks its nuclear translocation, reprograms the expression of immune-response-related genes and, as a consequence, enhances the anti-tumour response to PD-1 blockade. Thus, our results reveal an acetylation-dependent regulation of PD-L1 nuclear localization that governs immune-response gene expression, and thereby advocate targeting PD-L1 translocation to enhance the efficacy of PD-1/PD-L1 blockade.